Compare United States Oil ETF (USO) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
United States Oil ETF vs State Street SPDR S&P Biotech ETF — how do they compare? United States Oil ETF trades at $148.2 (market cap $1.90B), while State Street SPDR S&P Biotech ETF trades at $153.75 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 5.3× United States Oil ETF's market cap, and United States Oil ETF is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold United States Oil ETF for 21 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| USO | XBI | |
|---|---|---|
Market Cap | $1.90B | $10.11B |
Volume | 5,932,922 | 12,903,266 |
52-Week High | $161.86 | $169.55 |
52-Week Low | $66.17 | $104.99 |
Typical Hold Time | 21 Days | 38 Days |
Sector | — | Broad Market / Factor |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USO is trading at $147.58, up 2.55% with a bullish technical signal supported by moving averages. Recent news highlights Middle East tensions affecting oil supply, with OPEC+ maintaining output targets and G-7 planning strategic oil releases. The stock shows strength above key support levels amid volatile energy market conditions.
The outlook remains cautiously optimistic given geopolitical risks and supply constraints. Investment opportunities include potential price appreciation from supply disruptions, while risks involve oil price volatility and regulatory pressures from climate litigation. Institutional sentiment appears mixed with neutral oscillators suggesting near-term consolidation.
XBI trades at $149.29, down 0.63% on the day, with technical indicators showing a bearish bias despite oversold RSI conditions. The ETF faces mixed sentiment with 100% hold ratings from analysts but positive catalysts from biotech breakthroughs. Recent news highlights XBI's 76% rally over the past year and ongoing M&A activity driving sector optimism.
Outlook remains cautiously optimistic with potential upside from cancer vaccine developments and sector consolidation, though high volatility and expense ratios relative to broader healthcare ETFs present risks. The ETF's modified equal-weight structure offers diversified exposure to 150+ biotech names, benefiting from improved capital access and clinical trial catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
